List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Post Menopausal Osteoporosis - Drug Profiles
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT
Jun 17, 2022: Voluntary announcement - First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China
Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS
Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System
Dec 23, 2021: Radius announces update on TYMLOS (abaloparatide) label
Dec 08, 2021: Radius announces results from the wearABLe trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis
Oct 06, 2021: Entera Bio presents positive phase 2 6-month bone mineral density data for oral PTH formulation at Late Breaker ASBMR Conference Session
Sep 22, 2021: Radius Health announces TYMLOS label and business update
Sep 01, 2021: Entera Bio selected for late breaking oral presentation of phase 2 6-month osteoporosis data at ASBMR 2021 Annual Meeting
Jan 25, 2021: Luye Pharma LY06006 completed the last dosing for all subjects in phase III Clinical in China
Dec 14, 2020: Samsung Bioepis initiates phase 3 clinical trial for SB16, proposed biosimilar to Prolia (Denosumab)
Oct 23, 2020: Boan Biotech receives EU clinical trials application approval for Denosumab injection
Sep 09, 2020: Radius Health announces scientific presentations on abaloparatide at ASBMR 2020 Annual Meeting
Sep 08, 2020: Radius Health: Enrollment completed for Phase 3 wearABLe trial
Aug 20, 2020: Entera Bio announces interim data from phase 2 clinical trial of EB613 in osteoporosis and second quarter 2020 financial results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Post Menopausal Osteoporosis - Dormant Projects, 2022
Post Menopausal Osteoporosis - Dormant Projects, 2022 (Contd..1)
Post Menopausal Osteoporosis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Companies Mentioned
• Ablynx NV
• Addpharma Inc
• Airsea (Taizhou) Pharmaceutical Ltd
• AlphaMab Co Ltd
• Alvotech SA
• Amgen Inc
• Aryogen Pharmed Co
• Beijing Kangleweishi Biotechnology Co Ltd
• Beijing Northland Biotech Co Ltd
• Biocon Ltd
• Celltrion Inc
• Clayton Biotechnologies Inc
• Clonz Biotech Pvt Ltd
• CSPC Pharmaceutical Group Ltd
• Eden Biologics Inc
• Eli Lilly and Co
• Entera Bio Ltd
• Enteris BioPharma Inc
• Enzene Biosciences Ltd
• Epygen Biotech Pvt Ltd
• Fresenius Kabi SwissBioSim GmbH
• Gedeon Richter Plc
• Genor BioPharma Co Ltd
• Hualan Biological Engineering Inc
• Intas Pharmaceuticals Ltd
• Ipsen SA
• Jiangsu Hansoh Pharmaceutical Group Co Ltd
• Jiangsu Hengrui Medicine Co Ltd
• Jiangsu T-mab BioPharma Co Ltd
• Lupin Ltd
• Luye Pharma Group Ltd
• Mabxience Holding SL
• Nano Intelligent Biomedical Engineering Corp
• Nanomedic Inc
• NeuClone Pty Ltd
• Paras Biopharmaceuticals Finland Oy
• Qilu Pharmaceutical Co Ltd
• Reliance Life Sciences Pvt Ltd
• Samsung Bioepis Co Ltd
• Sandoz International GmbH
• Shandong New Time Pharmaceutical Co Ltd
• Shanghai Henlius Biotech Inc
• Shanghai Mab Venture Biopharm Co Ltd
• Shenzhen Salubris Pharmaceuticals Co Ltd
• Takeda Pharmaceutical Co Ltd
• Teva Pharmaceutical Industries Ltd
• Uni-Bio Science Group Ltd
• Wuxi Hebang Biotechnology Co Ltd